the design of the sunrise trial was supported by promising data from our prior phase iib second-line nsclc trial in the same indication , which final data was presented at the 2013 american society of clinical oncology annual meeting . in december 2013 , we initiated the phase iii sunrise trial and patient enrollment is ongoing . in addition , in january 2014 , we announced that bavituximab received fda fast track designation for combination with docetaxel in patients with previously-treated non-squamous nsclc . the phase iii sunrise trial is a randomized , double-blind , placebo-controlled trial evaluating bavituximab plus docetaxel versus docetaxel plus placebo in approximately 600 patients at clinical sites worldwide . the trial is enrolling patients with stage iiib/iv non-squamous nsclc who have progressed after standard front-line treatment . patients are randomized into one of two treatment arms . one treatment arm receives docetaxel ( 75 mg/m 2 ) , up to six 21-day cycles , in combination with bavituximab ( 3 mg/kg ) weekly until progression or toxicity . the other treatment receives docetaxel ( 75 mg/m 2 ) , up to six 21-day cycles , in combination with placebo weekly until progression or toxicity . the primary endpoint of the trial is overall survival . bavituximab in front-line nsclc this investigator-sponsored phase ib trial is designed to assess bavituximab with pemetrexed and carboplatin in up to 25 patients with locally advanced or metastatic nsclc . interim data conducted on a small number of patients showed encouraging response rates with the combination of carboplatin , pemetrexed and bavituximab . patient enrollment is complete and additional data is expected during fiscal year 2015. bavituximab in her2-negative metastatic breast cancer ( mbc ) this investigator-sponsored phase i trial was designed to assess bavituximab combined with paclitaxel in up to 14 patients with her2-negative metastatic breast cancer . interim data presented at asco in june 2013 , reported that , from 13 evaluable patients , 85 % of patients achieved an objective tumor response , including 15 % of patients achieving a complete response measured in accordance with recist criteria . patient enrollment is complete and final data from this study is anticipated during fiscal year 2015. bavituximab in advanced liver cancer this ongoing investigator-sponsored phase i/ii trial is designed to assess bavituximab combined with sorafenib in up to 48 patients with advanced liver cancer ( “ hepatocellular carcinoma ” or “ hcc ” ) . data presented at aacr in april 2012 showed that of the nine patients enrolled in the phase i portion of the study , no dose-limiting toxicities or serious adverse events were observed and the trial is currently enrolling the phase ii part of the study . 43 bavituximab in rectal adenocarcinoma this ongoing investigator-sponsored phase i trial is designed to assess bavituximab in combination with capecitabine and radiation therapy in up to 18 patients with stage ii or iii rectal adenocarcinoma . the primary endpoint is to determine the safety , feasibility and tolerability with a standard platform of capecitabine and radiation therapy . secondary endpoints include overall response rate and histopathological response in patients . this trial continues to enroll and dose patients . bavituximab in advanced melanoma in april 2014 , we announced the opening of an investigator-sponsored phase ib trial designed to assess bavituximab in combination with ipilimumab in up to 24 patients with advanced melanoma . the primary endpoint is to determine safety , feasibility and tolerability . secondary endpoints include measurements of disease control rate and overall survival . this trial is open for enrollment . ps-targeting molecular imaging program ( pgn650 ) in addition to the potential for our ps-targeting antibodies to treat cancer , we believe these antibodies may have broad potential for the imaging and diagnosis of multiple diseases , including cancer . ps-targeting antibodies are able to target diseases that present ps on the surface of distressed cells , which we believe is present in multiple disease settings . in oncology , ps is a molecule usually located inside the membrane of healthy cells , but “ flips ” and becomes exposed on the outside of cells in the tumor microenvironment , creating a specific target for the imaging of multiple solid tumor types . our initial clinical candidate is pgn650 , a first-in-class ps-targeting f ( ab ' ) 2 fully human monoclonal antibody fragment joined to the positron emission tomography ( “ pet ” ) imaging radio-isotope iodine-124 that represents a potential new approach to imaging cancer . in preclinical studies , pgn650 accumulates in tumors and provides exceedingly clear in vivo tumor images . the initial goal for the pgn650 program is to further validate the broad nature of the ps-targeting platform in the clinic . our current pgn650 clinical trial evaluating pgn650 imaging in multiple solid tumor types in up to 12 patients was filed under an exploratory ind with the fda . the primary goal of the trial is to estimate radiation dosimetry in critical and non-critical organs and secondary trial objectives include tumor imaging and safety . results from this study may open the door for multiple applications including the development of antibody drug conjugates , the use of pgn650 to monitor the effectiveness of current standard cancer treatments , and the ability to potentially select patients that may benefit from bavituximab-based treatment . patients receive an imaging dose followed by three pet images . successful results from this trial could support several promising new areas of research in the imaging and diagnostic fields . this trial continues to enroll and dose patients . integrated biomanufacturing subsidiary in addition to our clinical research and development efforts , we operate a wholly-owned ( current good manufacturing practices ( “ cgmp ” ) ) contract manufacturing subsidiary , avid bioservices , inc. ( “ avid ” ) . story_separator_special_tag we recognize revenue when all of the following criteria are met : ( i ) persuasive evidence of an arrangement exists , ( ii ) delivery ( or passage of title ) has occurred or services have been rendered , ( iii ) the seller 's price to the buyer is fixed or determinable , and ( iv ) collectability is reasonably assured . we also comply with the authoritative guidance for revenue recognition regarding arrangements with multiple deliverables . contract manufacturing revenue revenue associated with contract manufacturing services provided by avid is recognized once the service has been rendered and or upon shipment ( or passage of title ) of the product to the customer . on occasion , we recognize revenue on a “ bill-and-hold ” basis in accordance with the authoritative guidance . under “ bill-and-hold ” arrangements , revenue is recognized once the product is complete and ready for shipment , title and risk of loss has passed to the customer , management receives a written request from the customer for “ bill-and-hold ” treatment , the product is segregated from other inventory , and no further performance obligations exist . in addition , we also follow the authoritative guidance when reporting revenue as gross when we act as a principal versus reporting revenue as net when we act as an agent . for transactions in which we act as a principal , have discretion to choose suppliers , bear credit risk and perform a substantive part of the services , revenue is recorded at the gross amount billed to a customer and costs associated with these reimbursements are reflected as a component of cost of sales for contract manufacturing services . any amounts received prior to satisfying our revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated financial statements . we also record a provision for estimated contract losses , if any , in the period in which they are determined . license revenue revenue associated with licensing agreements primarily consists of non-refundable upfront license fees , non-refundable annual license fees and milestone payments . non-refundable upfront license fees received under license agreements , whereby continued performance or future obligations are considered inconsequential to the relevant license technology , are recognized as revenue upon delivery of the technology . if a licensing agreement has multiple elements , we analyze each element of our licensing agreements and consider a variety of factors in determining the appropriate method of revenue recognition of each element . 50 multiple element arrangements . prior to the adoption of accounting standards update ( “ asu ” ) no . 2009-13 on may 1 , 2011 , if a license agreement has multiple element arrangements , we analyze and determine whether the deliverables , which often include performance obligations , can be separated or whether they must be accounted for as a single unit of accounting in accordance with the authoritative guidance . under multiple element arrangements , we recognize revenue for delivered elements only when the delivered element has stand-alone value and we have objective and reliable evidence of fair value for each undelivered element . if the fair value of any undelivered element included in a multiple element arrangement can not be objectively determined , the arrangement would then be accounted for as a single unit of accounting , and revenue is recognized over the estimated period of when the performance obligation ( s ) are performed . in addition , under certain circumstances , when there is objective and reliable evidence of the fair value of the undelivered items in an arrangement , but no such evidence for the delivered items , we utilize the residual method to allocate the consideration received under the arrangement . under the residual method , the amount of consideration allocated to delivered items equals the total arrangement consideration less the aggregate fair value of the undelivered items , and revenue is recognized upon delivery of the undelivered items based on the relative fair value of the undelivered items . for licensing agreements or material modifications of existing licensing agreements entered into after may 1 , 2011 , we follow the provisions of asu no . 2009-13. if a licensing agreement includes multiple elements , we identify which deliverables represent separate units of accounting , and then determine how the arrangement consideration should be allocated among the separate units of accounting , which may require the use of significant judgment . if a licensing agreement includes multiple elements , a delivered item is considered a separate unit of accounting if both of the following criteria are met : 1. the delivered item has value to the licensing partner on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement ; 2. if the arrangement includes a general right of return relative to the delivered item , delivery or performance of the undelivered item is considered probable and substantially in the company 's control . arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price . the relative selling price for each deliverable is determined using vendor specific objective evidence ( “ vsoe ” ) of selling price or third-party evidence of selling price if vsoe does not exist . if neither vsoe nor third-party evidence of selling price exists , we use our best estimate of the selling price for the deliverable . the amount of allocable arrangement consideration is limited to amounts that are fixed or determinable . the consideration received is allocated among the separate units of accounting , and the applicable revenue recognition criteria are applied to each of the separate units . changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement . milestone payments . effective may 1 , 2011

cash used in operating activities . net cash used in operating activities represents our ( i ) net loss , as reported , ( ii ) less non-cash operating expenses , and ( iii ) net changes in the timing of cash flows as reflected by the changes in operating assets and liabilities , as described in the below table : 54 replace_table_token_8_th net cash used in operating activities for the year ended april 30 , 2014 was $ 28,254,000 compared to $ 20,926,000 for the year ended april 30 , 2013 , representing an increase of $ 7,328,000. this increase in net cash used in operating activities was due to an increase of $ 4,611,000 in net loss reported for fiscal year 2014 after deducting non-cash operating expenses combined with a net change in operating assets and liabilities of $ 2,717,000. the increase in our fiscal year net loss was primarily due to current year increases in research and development expenses , selling , general and administrative expenses and cost of contract manufacturing , offset by an increase in total revenues and a decrease in loss on early extinguishment of debt . the net change in operating assets and liabilities between fiscal year 2014 and fiscal year 2013 was primarily due to decreases in customer deposits and accrued payroll combined with increase in prepaid expenses and other current assets , which were primarily offset by an increase in accrued clinical trial and related fees . cash used in investing activities .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash used in operating activities . net cash used in operating activities represents our ( i ) net loss , as reported , ( ii ) less non-cash operating expenses , and ( iii ) net changes in the timing of cash flows as reflected by the changes in operating assets and liabilities , as described in the below table : 54 replace_table_token_8_th net cash used in operating activities for the year ended april 30 , 2014 was $ 28,254,000 compared to $ 20,926,000 for the year ended april 30 , 2013 , representing an increase of $ 7,328,000. this increase in net cash used in operating activities was due to an increase of $ 4,611,000 in net loss reported for fiscal year 2014 after deducting non-cash operating expenses combined with a net change in operating assets and liabilities of $ 2,717,000. the increase in our fiscal year net loss was primarily due to current year increases in research and development expenses , selling , general and administrative expenses and cost of contract manufacturing , offset by an increase in total revenues and a decrease in loss on early extinguishment of debt . the net change in operating assets and liabilities between fiscal year 2014 and fiscal year 2013 was primarily due to decreases in customer deposits and accrued payroll combined with increase in prepaid expenses and other current assets , which were primarily offset by an increase in accrued clinical trial and related fees . cash used in investing activities .
```    
 Suspicious Activity Report : the design of the sunrise trial was supported by promising data from our prior phase iib second-line nsclc trial in the same indication , which final data was presented at the 2013 american society of clinical oncology annual meeting . in december 2013 , we initiated the phase iii sunrise trial and patient enrollment is ongoing . in addition , in january 2014 , we announced that bavituximab received fda fast track designation for combination with docetaxel in patients with previously-treated non-squamous nsclc . the phase iii sunrise trial is a randomized , double-blind , placebo-controlled trial evaluating bavituximab plus docetaxel versus docetaxel plus placebo in approximately 600 patients at clinical sites worldwide . the trial is enrolling patients with stage iiib/iv non-squamous nsclc who have progressed after standard front-line treatment . patients are randomized into one of two treatment arms . one treatment arm receives docetaxel ( 75 mg/m 2 ) , up to six 21-day cycles , in combination with bavituximab ( 3 mg/kg ) weekly until progression or toxicity . the other treatment receives docetaxel ( 75 mg/m 2 ) , up to six 21-day cycles , in combination with placebo weekly until progression or toxicity . the primary endpoint of the trial is overall survival . bavituximab in front-line nsclc this investigator-sponsored phase ib trial is designed to assess bavituximab with pemetrexed and carboplatin in up to 25 patients with locally advanced or metastatic nsclc . interim data conducted on a small number of patients showed encouraging response rates with the combination of carboplatin , pemetrexed and bavituximab . patient enrollment is complete and additional data is expected during fiscal year 2015. bavituximab in her2-negative metastatic breast cancer ( mbc ) this investigator-sponsored phase i trial was designed to assess bavituximab combined with paclitaxel in up to 14 patients with her2-negative metastatic breast cancer . interim data presented at asco in june 2013 , reported that , from 13 evaluable patients , 85 % of patients achieved an objective tumor response , including 15 % of patients achieving a complete response measured in accordance with recist criteria . patient enrollment is complete and final data from this study is anticipated during fiscal year 2015. bavituximab in advanced liver cancer this ongoing investigator-sponsored phase i/ii trial is designed to assess bavituximab combined with sorafenib in up to 48 patients with advanced liver cancer ( “ hepatocellular carcinoma ” or “ hcc ” ) . data presented at aacr in april 2012 showed that of the nine patients enrolled in the phase i portion of the study , no dose-limiting toxicities or serious adverse events were observed and the trial is currently enrolling the phase ii part of the study . 43 bavituximab in rectal adenocarcinoma this ongoing investigator-sponsored phase i trial is designed to assess bavituximab in combination with capecitabine and radiation therapy in up to 18 patients with stage ii or iii rectal adenocarcinoma . the primary endpoint is to determine the safety , feasibility and tolerability with a standard platform of capecitabine and radiation therapy . secondary endpoints include overall response rate and histopathological response in patients . this trial continues to enroll and dose patients . bavituximab in advanced melanoma in april 2014 , we announced the opening of an investigator-sponsored phase ib trial designed to assess bavituximab in combination with ipilimumab in up to 24 patients with advanced melanoma . the primary endpoint is to determine safety , feasibility and tolerability . secondary endpoints include measurements of disease control rate and overall survival . this trial is open for enrollment . ps-targeting molecular imaging program ( pgn650 ) in addition to the potential for our ps-targeting antibodies to treat cancer , we believe these antibodies may have broad potential for the imaging and diagnosis of multiple diseases , including cancer . ps-targeting antibodies are able to target diseases that present ps on the surface of distressed cells , which we believe is present in multiple disease settings . in oncology , ps is a molecule usually located inside the membrane of healthy cells , but “ flips ” and becomes exposed on the outside of cells in the tumor microenvironment , creating a specific target for the imaging of multiple solid tumor types . our initial clinical candidate is pgn650 , a first-in-class ps-targeting f ( ab ' ) 2 fully human monoclonal antibody fragment joined to the positron emission tomography ( “ pet ” ) imaging radio-isotope iodine-124 that represents a potential new approach to imaging cancer . in preclinical studies , pgn650 accumulates in tumors and provides exceedingly clear in vivo tumor images . the initial goal for the pgn650 program is to further validate the broad nature of the ps-targeting platform in the clinic . our current pgn650 clinical trial evaluating pgn650 imaging in multiple solid tumor types in up to 12 patients was filed under an exploratory ind with the fda . the primary goal of the trial is to estimate radiation dosimetry in critical and non-critical organs and secondary trial objectives include tumor imaging and safety . results from this study may open the door for multiple applications including the development of antibody drug conjugates , the use of pgn650 to monitor the effectiveness of current standard cancer treatments , and the ability to potentially select patients that may benefit from bavituximab-based treatment . patients receive an imaging dose followed by three pet images . successful results from this trial could support several promising new areas of research in the imaging and diagnostic fields . this trial continues to enroll and dose patients . integrated biomanufacturing subsidiary in addition to our clinical research and development efforts , we operate a wholly-owned ( current good manufacturing practices ( “ cgmp ” ) ) contract manufacturing subsidiary , avid bioservices , inc. ( “ avid ” ) . story_separator_special_tag we recognize revenue when all of the following criteria are met : ( i ) persuasive evidence of an arrangement exists , ( ii ) delivery ( or passage of title ) has occurred or services have been rendered , ( iii ) the seller 's price to the buyer is fixed or determinable , and ( iv ) collectability is reasonably assured . we also comply with the authoritative guidance for revenue recognition regarding arrangements with multiple deliverables . contract manufacturing revenue revenue associated with contract manufacturing services provided by avid is recognized once the service has been rendered and or upon shipment ( or passage of title ) of the product to the customer . on occasion , we recognize revenue on a “ bill-and-hold ” basis in accordance with the authoritative guidance . under “ bill-and-hold ” arrangements , revenue is recognized once the product is complete and ready for shipment , title and risk of loss has passed to the customer , management receives a written request from the customer for “ bill-and-hold ” treatment , the product is segregated from other inventory , and no further performance obligations exist . in addition , we also follow the authoritative guidance when reporting revenue as gross when we act as a principal versus reporting revenue as net when we act as an agent . for transactions in which we act as a principal , have discretion to choose suppliers , bear credit risk and perform a substantive part of the services , revenue is recorded at the gross amount billed to a customer and costs associated with these reimbursements are reflected as a component of cost of sales for contract manufacturing services . any amounts received prior to satisfying our revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated financial statements . we also record a provision for estimated contract losses , if any , in the period in which they are determined . license revenue revenue associated with licensing agreements primarily consists of non-refundable upfront license fees , non-refundable annual license fees and milestone payments . non-refundable upfront license fees received under license agreements , whereby continued performance or future obligations are considered inconsequential to the relevant license technology , are recognized as revenue upon delivery of the technology . if a licensing agreement has multiple elements , we analyze each element of our licensing agreements and consider a variety of factors in determining the appropriate method of revenue recognition of each element . 50 multiple element arrangements . prior to the adoption of accounting standards update ( “ asu ” ) no . 2009-13 on may 1 , 2011 , if a license agreement has multiple element arrangements , we analyze and determine whether the deliverables , which often include performance obligations , can be separated or whether they must be accounted for as a single unit of accounting in accordance with the authoritative guidance . under multiple element arrangements , we recognize revenue for delivered elements only when the delivered element has stand-alone value and we have objective and reliable evidence of fair value for each undelivered element . if the fair value of any undelivered element included in a multiple element arrangement can not be objectively determined , the arrangement would then be accounted for as a single unit of accounting , and revenue is recognized over the estimated period of when the performance obligation ( s ) are performed . in addition , under certain circumstances , when there is objective and reliable evidence of the fair value of the undelivered items in an arrangement , but no such evidence for the delivered items , we utilize the residual method to allocate the consideration received under the arrangement . under the residual method , the amount of consideration allocated to delivered items equals the total arrangement consideration less the aggregate fair value of the undelivered items , and revenue is recognized upon delivery of the undelivered items based on the relative fair value of the undelivered items . for licensing agreements or material modifications of existing licensing agreements entered into after may 1 , 2011 , we follow the provisions of asu no . 2009-13. if a licensing agreement includes multiple elements , we identify which deliverables represent separate units of accounting , and then determine how the arrangement consideration should be allocated among the separate units of accounting , which may require the use of significant judgment . if a licensing agreement includes multiple elements , a delivered item is considered a separate unit of accounting if both of the following criteria are met : 1. the delivered item has value to the licensing partner on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement ; 2. if the arrangement includes a general right of return relative to the delivered item , delivery or performance of the undelivered item is considered probable and substantially in the company 's control . arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price . the relative selling price for each deliverable is determined using vendor specific objective evidence ( “ vsoe ” ) of selling price or third-party evidence of selling price if vsoe does not exist . if neither vsoe nor third-party evidence of selling price exists , we use our best estimate of the selling price for the deliverable . the amount of allocable arrangement consideration is limited to amounts that are fixed or determinable . the consideration received is allocated among the separate units of accounting , and the applicable revenue recognition criteria are applied to each of the separate units . changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement . milestone payments . effective may 1 , 2011

